Global Kidney Cancer Medicine Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Kidney Cancer Medicine Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application
Kidney cancer -- also called renal cancer -- is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Almost all kidney cancers first appear in the lining of tiny tubes (tubules) in the kidney. This type of kidney cancer is called renal cell carcinoma.
Renal cell carcinoma (RCC) is a common malignant tumor worldwide, referred to as kidney cancer. According to the World Health Organization, the global incidence of kidney cancer accounts for 2% to 3% of systemic tumors. Among malignant tumors of the urinary system, its incidence is second only to bladder cancer, and it is increasing year by year. In recent years, targeted therapy and precision therapy have become standard treatments for kidney cancer.
Kidney Cancer Medicine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Kidney Cancer Medicine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Renal Cell Carcinoma (RCC) and Transitional Cell Carcinoma (TCC) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Kidney Cancer Medicine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Kidney Cancer Medicine key companies include Pfizer, Bristol-Myers Squibb, Roche, GSK, Novartis, Bayer, Merck & Co., Exelixis and Takeda, etc. Pfizer, Bristol-Myers Squibb, Roche are top 3 players and held % share in total in 2022.
Kidney Cancer Medicine can be divided into Monoclonal Antibody, mTOR Inhibitors, Kinase Inhibitors and Other, etc. Monoclonal Antibody is the mainstream product in the market, accounting for % share globally in 2022.
Kidney Cancer Medicine is widely used in various fields, such as Renal Cell Carcinoma (RCC) and Transitional Cell Carcinoma (TCC), etc. Renal Cell Carcinoma (RCC) provides greatest supports to the Kidney Cancer Medicine industry development. In 2022, global % share of Kidney Cancer Medicine went into Renal Cell Carcinoma (RCC) filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Kidney Cancer Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Pfizer
Bristol-Myers Squibb
Roche
GSK
Novartis
Bayer
Merck & Co.
Exelixis
Takeda
Eisai
CTTQ
AVEO Oncology
Everest Pharm
Cipla
NATCO
Beacon Pharma
SAMARTH
Segment by Type
Monoclonal Antibody
mTOR Inhibitors
Kinase Inhibitors
Other
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Kidney Cancer Medicine market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Kidney Cancer Medicine introduction, etc. Kidney Cancer Medicine Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Kidney Cancer Medicine market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Renal cell carcinoma (RCC) is a common malignant tumor worldwide, referred to as kidney cancer. According to the World Health Organization, the global incidence of kidney cancer accounts for 2% to 3% of systemic tumors. Among malignant tumors of the urinary system, its incidence is second only to bladder cancer, and it is increasing year by year. In recent years, targeted therapy and precision therapy have become standard treatments for kidney cancer.
Kidney Cancer Medicine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Kidney Cancer Medicine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Renal Cell Carcinoma (RCC) and Transitional Cell Carcinoma (TCC) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Kidney Cancer Medicine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Kidney Cancer Medicine key companies include Pfizer, Bristol-Myers Squibb, Roche, GSK, Novartis, Bayer, Merck & Co., Exelixis and Takeda, etc. Pfizer, Bristol-Myers Squibb, Roche are top 3 players and held % share in total in 2022.
Kidney Cancer Medicine can be divided into Monoclonal Antibody, mTOR Inhibitors, Kinase Inhibitors and Other, etc. Monoclonal Antibody is the mainstream product in the market, accounting for % share globally in 2022.
Kidney Cancer Medicine is widely used in various fields, such as Renal Cell Carcinoma (RCC) and Transitional Cell Carcinoma (TCC), etc. Renal Cell Carcinoma (RCC) provides greatest supports to the Kidney Cancer Medicine industry development. In 2022, global % share of Kidney Cancer Medicine went into Renal Cell Carcinoma (RCC) filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Kidney Cancer Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Pfizer
Bristol-Myers Squibb
Roche
GSK
Novartis
Bayer
Merck & Co.
Exelixis
Takeda
Eisai
CTTQ
AVEO Oncology
Everest Pharm
Cipla
NATCO
Beacon Pharma
SAMARTH
Segment by Type
Monoclonal Antibody
mTOR Inhibitors
Kinase Inhibitors
Other
Segment by Application
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Kidney Cancer Medicine market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Kidney Cancer Medicine introduction, etc. Kidney Cancer Medicine Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Kidney Cancer Medicine market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices